Brainsway (NASDAQ:BWAY) Receives Buy Rating from HC Wainwright

Brainsway (NASDAQ:BWAY)‘s stock had its “buy” rating restated by HC Wainwright in a research report issued to clients and investors on Tuesday, Benzinga reports. They currently have a $19.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 32.36% from the stock’s previous close.

A number of other research firms have also commented on BWAY. Wall Street Zen raised Brainsway from a “hold” rating to a “buy” rating in a research note on Sunday, August 2nd. New Street Research reissued a “buy” rating on shares of Brainsway in a research report on Friday, July 24th. Weiss Ratings lowered shares of Brainsway from a “buy (b-)” rating to a “hold (c+)” rating in a report on Wednesday, August 19th. LADENBURG THALM/SH SH boosted their price target on shares of Brainsway from $18.00 to $18.80 and gave the stock a “buy” rating in a research report on Thursday, August 13th. Finally, BTIG Research upped their price objective on shares of Brainsway from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Five analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $18.20.

Brainsway Stock Performance

Shares of NASDAQ:BWAY traded up $0.20 during mid-day trading on Tuesday, reaching $14.36. 33,105 shares of the company’s stock were exchanged, compared to its average volume of 157,677. Brainsway has a twelve month low of $7.14 and a twelve month high of $17.40. The firm has a market capitalization of $577.21 million, a price-to-earnings ratio of 32.63 and a beta of 1.25. The business’s fifty day moving average price is $15.18 and its 200-day moving average price is $14.72.

Brainsway (NASDAQ:BWAY) last posted its quarterly earnings data on Wednesday, August 12th. The company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.10 by $0.04. The business had revenue of $17.11 million during the quarter, compared to the consensus estimate of $16.54 million. Brainsway had a return on equity of 12.74% and a net margin of 15.65%. Analysts predict that Brainsway will post 0.33 EPS for the current fiscal year.

Institutional Trading of Brainsway

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Masters Capital Management LLC raised its holdings in shares of Brainsway by 65.0% in the 1st quarter. Masters Capital Management LLC now owns 1,650,000 shares of the company’s stock worth $21,928,000 after acquiring an additional 650,000 shares during the last quarter. Renaissance Technologies LLC boosted its stake in Brainsway by 87.2% during the 1st quarter. Renaissance Technologies LLC now owns 518,420 shares of the company’s stock valued at $6,890,000 after purchasing an additional 241,560 shares during the last quarter. Y.D. More Investments Ltd boosted its stake in Brainsway by 136.6% during the 1st quarter. Y.D. More Investments Ltd now owns 272,004 shares of the company’s stock valued at $3,615,000 after purchasing an additional 157,042 shares during the last quarter. Sei Investments Co. increased its holdings in Brainsway by 262.5% during the 1st quarter. Sei Investments Co. now owns 226,378 shares of the company’s stock worth $3,009,000 after purchasing an additional 163,925 shares in the last quarter. Finally, ARK Investment Management LLC bought a new stake in Brainsway during the 4th quarter worth approximately $2,422,000. Institutional investors own 30.11% of the company’s stock.

About Brainsway

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.